Additionally, the authors showed that the combination of the IDO1 inhibitor epacadostat and a purinergic receptor antagonist was able to rescue T cell function and proliferation in mouse models for ovarian cancer [80]. This evidence concerns the gene IDO1 and ovarian carcinoma.